Longitudinal Changes in Serum HER-2/neu Oncoprotein Levels in Trastuzumab-treated Metastatic Breast Cancer Patients

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1083-1089

  Bethune Volters, Anne ^a   Labroquere, Marc ^a   Guepratte, Sylvie ^a   Hacene, Kamel ^a   Neumann, Rainer ^b   Carney, Walter ^c   Pichon, Marie France ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b BAYER AG   (Germany)

^c Oncogene Science   (United States)

Author keywords

Breast neoplasms; HER 2 neu; Serum; Trastuzumab

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MEDICAL DECISION MAKING; METASTASIS; ONCOGENE NEU; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 2442432730     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aaronson SA: Growth factors and cancer. Science 254: 1146-53, 1991.
2. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-9, 1985.
3. Kurebayshi J: Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 8: 45-51, 2001.
4. Slamon DJ, Clark GM, Wong SG Levin WJ, Ullrich A and McGuire WI: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-82, 1987.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-92, 2001.
6. Zabrecky JR, Lam T, McKenzie SJ and Carney W: The extracellular domain of p185 is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266: 1716-20, 1991.
7. Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR et al: Detection and quantitation of the human neu oncoprotein. J Tumour Marker Oncol 6: 53-72, 1991.
8. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L et al: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a preparation of breast cancer patients. J Clin Oncol 10: 436-43, 1992.
9. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G and Colnaghi MI: The extracellular domain of the c-erbB-2 oncoprotein is released from tumour cells by proteolytic cleavage. Oncogene 8: 2917-23, 1993.
10. Kaptain S, Tan LK and Chen B: HER-2/neu and breast cancer. Diag Mol Pathol 10: 139-52, 2001.
11. Ross JS and Fletcher JA: HER-2/neu (c-erbB2) gene and protein in breast cancer. Am J Clin Pathol 112: S53-67, 1999.
12. Carney WP: The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Laboratory Medicine 34: 58-64, 2003.
13. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali D, Trimpe KL and Carney WP: Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4: 43-8, 1989.
14. Miller R and Siegmund D: Maximally selected Chi-square statistics. Biometrics 38: 1011-1016, 1982.
15. Kaplan EL and Meier PO: Non parametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
16. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
17. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY and Morris DL: Automated assay for HER-2/neu in serum. Clin Chem 46: 2:175-82, 2000.
18. Ali SA, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA et al: Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 48: 1314-20, 2002.
19. Schondorf T, Hoopman M, Warm M, Neumann R, Thomas A, Gohring UJ et al: Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin Chem 48: 1360-1362, 2002.
20. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808, 2002.
21. Baselga J, Tripathy D, Mendelsohn J, Baugham S, Benz C, Dantis L et al: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Sem Oncol 26: suppl 4, 78-83, 1999.
22. Lüftner DI, Schaller G, Henschke P, Felsenstein S, Geppert R and Possinger K: Evaluation of serum HER-2/neu for outcome assessment and monitoring of Herceptin plus combination chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 76: suppl 1: 427, 2002.
23. Nunes RA, Burstein HJ, Friedman P, Hemken P, Roberts L, Carney W et al: Serial analysis of circulating tumour cells (CTCs) and serum HER2 in HER2 positive metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (Herceptin; H) and vinorelbine (N). Proc ASCO 21: A1766, 2002.
24. Kostler WJ, Schwab B, Singer C, Neumann R, Marton E, Brodowicz T et al: Serial monitoring of serum HER-2/neu extracellular domain (ECD) can predict response to trastuzumab-based therapy in patients with breast cancer. Proc ASCO 21: A64, 2002.